ORIGINAL_ARTICLE
Partner HIV Status Disclosure and Serodiscordant Couples Rates Among Infected Adults in an Urban Community in South-East Nigeria: A Cross-sectional Study
Background and aim: The Human Immunodeficiency Virus (HIV) is a global pandemic, with sub-Saharan Africa contributing to the majority of cases of HIV. There have been various challenges towards the treatment and prevention of HIV infection in our environment, and these include; low uptake of voluntary counselling and testing, high discrimination rate, and non-disclosure of a positive status to sexual partners. This study aimed to determine the prevalence and predictors of partner disclosure of seropositive status amongst HIV-infected adults and the serodiscordant rate amongst sexual partners.Materials and methods: An interviewer-administered structured questionnaire was used to obtain data from 380 HIV-infected adults aged 18 years and above. Descriptive statistics were used to summarize obtained data. Multiple logistic regression was done to show predictors of disclosure. P-value.Results: The prevalence of partner disclosure of HIV positive status was 91.8%, and the serodiscordant rate was 38.9%, with 52.4% of participants having a positive partner and 8.7% being unaware of their partner's status. Marital status and knowledge of partner's HIV status were significantly associated with disclosure.Conclusion: There was a high prevalence rate of partner disclosure of HIV status amongst infected participants in our environment. Couple counselling should be encouraged to allow for mutual disclosure. Also, counselling on the importance of partner disclosure of status should be intensified, especially among unmarried persons, while efforts should be made to reduce the stigmatization rate.
http://www.ijsrdms.com/article_129507_6afd8c1f29df74f6bf67a6f8633e4604.pdf
2021-06-01
55
60
10.30485/ijsrdms.2021.275123.1129
Disclosure
HIV
partner
Serodiscordant couples
Ethel
Nwachukwu
etheloluchi1@gmail.com
1
Department of Family Medicine, School of Medicine, Nnamdi Azikiwe University, Teaching Hospital (NAUTH) Nnewi, Anambra, Nigeria
LEAD_AUTHOR
Chika
Ofiaeli
ofiaelichika@yahoo.com
2
Department of Family Medicine, School of Medicine, Nnamdi Azikiwe University, Teaching Hospital (NAUTH) Nnewi, Anambra, Nigeria
AUTHOR
Owulo
Agada
agadaski@yahoo.com
3
Department of Family Medicine, School of Medicine, Nnamdi Azikiwe University, Teaching Hospital (NAUTH) Nnewi, Anambra, Nigeria
AUTHOR
Obinna
Nwankwo
kingsclopsy@gmail.com
4
Department of Family Medicine, School of Medicine, Nnamdi Azikiwe University, Teaching Hospital (NAUTH) Nnewi, Anambra, Nigeria
AUTHOR
Ifeanyi
Njoku
ifeanyinjoku2@gmail.com
5
Department of Community Medicine and Primary Health Care, School of Medicine, Nnamdi Azikiwe University (NAU) Awka, Anambra, Nigeria
AUTHOR
[1] WHO.HIV/AIDS.https://www.who.int/news-room/fact-sheets/detail/hiv-aids. 2021.
1
[2] WHO. HIV Status Disclosure to Sexual Partners: Rates, Barriers and Outcomes for Women. http://www.who.int/gender/documents/en/. 2021.
2
[3] Kamanga G, Brown L, Jawati P, Chiwanda D, Nyirenda N. Maximizing HIV partner notification opportunities for index patients and their sexual partners in Malawi. Malawi Medical Journal. 2015;27(4):140-4. DOI: 10.4314/mmj.v27i4.5.
3
[4] Dessalegn NG, Hailemichael RG, Shewa-Amare A, Sawleshwarkar S, Lodebo B, Amberbir A, et al. HIV Disclosure: HIV-positive status disclosure to sexual partners among individuals receiving HIV care in Addis Ababa, Ethiopia. PloS one. 2019;14(2):e0211967. https://doi.org/10.1371/journal.pone.0211967.
4
[5] Kalichman SC, Kalichman MO, Cherry C, Grebler T. HIV disclosure and transmission risks to sex partners among HIV-positive men. AIDS patient care and STDs. 2016;30(5):221-8. https://doi.org/10.1089/apc.2015.0333.
5
[6] Dahlui M, Azahar N, Bulgiba A, Zaki R, Oche OM, Adekunjo FO, et al. HIV/AIDS related stigma and discrimination against PLWHA in Nigerian population. PloS one. 2015;10(12):e0143749. https://doi.org/10.1371/journal.pone.0143749.
6
[7] Oke OO, Akinboro AO, Olanrewaju FO, Oke OA, Omololu AS. Assessment of HIV-related stigma and determinants among people living with HIV/AIDS in Abeokuta, Nigeria: A cross-sectional study. SAGE open medicine. 2019;7:2050312119869109. https://doi.org/10.1177/2050312119869109.
7
[8] Shodimu MA, Yusuf OB, Akinyemi JO, Fagbamigbe AF, Bamgboye EA, Ngige E, et al. Determinants of perceived stigmatizing and discriminating attitudes towards people living with HIV/AIDS among women of reproductive age in Nigeria. Journal of AIDS and HIV Research. 2017;9(6):139-51. https://doi.org/10.5897/JAHR2016.0391.
8
[9] Odiachi A, Erekaha S, Cornelius LJ, Isah C, Ramadhani HO, Rapoport L, et al. HIV status disclosure to male partners among rural Nigerian women along the prevention of mother-to-child transmission of HIV cascade: a mixed methods study. Reproductive health. 2018;15(1):1-2. https://doi.org/10.1186/s12978-018-0474-y.
9
[10] Bibiana NE, Emmanuel PO, Amos D, Ramsey YM, Idris AN. Knowledge, attitude and factors affecting voluntary HIV counseling and testing services among women of reproductive age group in an Abuja Suburb community, Nigeria. Medical Journal of Zambia. 2018;45(1):13-22.
10
[11] Ijadunola MY, Ojo TO, Ogunlesi O, Adewumi A, Kolade RO, Thomas B. Perceived hindrances and factors influencing acceptability of HIV/AIDS counseling and testing among commercial drivers in Ile-Ife. Nigerian Journal of Health Sciences. 2015;15(1):30. DOI: 10.4103/1596-4078.171371.
11
[12] Chijioke Udeh S. Socio-Cultural Factors Influencing HIV/AIDS Prevalence in Nigeria; A Review. International Online Medical Council, 2020https://www.iomcworld.org/abstract/sociocultural-factors-influencing-hivaids-prevalence-in-nigeria-a-review-57123.html. 2021.
12
[13] Habte E, Yami A, Alemseged F, Abdissa Y, Deribe K, Memiah P, et al. Predictors of HIV serodiscordance among couples in southwestern Ethiopia. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2015;14(3):234-40. https://doi.org/10.1177/2325957413488177.
13
[14] Ngilangwa DP, Ochako R, Mboya BA, Noronha RH, Mgomella GS. Prevalence and predictors of HIV sero-discordance among cohabiting couples tested in northern Tanzania. Pan African Medical Journal. 2015;22(1). DOI: 10.11604/pamj.2015.22.275.5961.
14
[15] Onovo AA, Nta IE, Onah AA, Okolo CA, Aliyu A, Dakum P, et al. Partner HIV serostatus disclosure and determinants of serodiscordance among prevention of mother to child transmission clients in Nigeria. BMC public health. 2015;15(1):1-1. https://doi.org/10.1186/s12889-015-2155-x
15
[16] Van Tam V, Alfven T, Phuc HD, Chuc NT, Hoa NP, Diwan V, et al. HIV sero-discordance among married HIV patients initiating anti-retroviral therapy in northern Vietnam. AIDS research and therapy. 2016;13(1):1-7. https://doi.org/10.1186/s12981-016-0124-9
16
[17] Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet. 2019 Jun 15;393(10189):2428-38. https://doi.org/10.1016/S0140-6736(19)30418-0.
17
[18] World Health Organization. Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at “substantial” risk. Geneva, Switzerland: WHO. 2015 Sep 30.
18
[19] Girum T, Yasin F, Wasie A, Shumbej T, Bekele F, Zeleke B. The effect of “universal test and treat” program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. AIDS Research and Therapy. 2020;17:1-9. https://doi.org/10.1186/s12981-020-00274-3.
19
[20] World Health Organization. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. World Health Organization; 2012.
20
[21] Dillnessa E, Enquselassie F. Couples voluntary counselling and testing among VCT clients in Addis Ababa, Ethiopia. Ethiopian medical journal. 2010;48(2):95-103.
21
[22] Israel GD. Determining Sample Size 1.http://edis.ifas.ufl.edu. 1992.
22
[23] Ebuenyi ID, Ogoina D, Ikuabe PO, Harry TC, Inatimi O, Chukwueke OU. Prevalence Pattern and Determinants of disclosure of HIV status in an anti retroviral therapy Clinic in the Niger Delta Region of Nigeria. African journal of infectious diseases. 2014;8(2):22-6. DOI: 10.4314/ajid.v8i2.2.
23
[24] Lifson AR, Workneh S, Hailemichael A, MacLehose RF, Horvath KJ, Hilk R, et al. Disclosure of HIV status among patients new to HIV care in Southern Ethiopia: role of perceived social support and other factors. AIDS care. 2020:1-6. https://doi.org/10.1080/09540121.2020.1785999.
24
[25] Damian DJ, Ngahatilwa D, Fadhili H, Mkiza JG, Mahande MJ, Ngocho JS, et al. Factors associated with HIV status disclosure to partners and its outcomes among HIV-positive women attending Care and Treatment Clinics at Kilimanjaro region, Tanzania. PloS one. 2019;14(3):e0211921. https://doi.org/10.1371/journal.pone.0211921.
25
[26] Okafor CN, Li MJ, Hucks-Ortiz C, Mayer KH, Shoptaw S. Disclosure of HIV status and HIV sexual transmission behaviors among HIV-positive black men who have sex with men in the BROTHERS (HPTN 061) study. Journal of Urban Health. 2020:692-703. https://doi.org/10.1007/s11524-020-00419-9.
26
[27] Meseret Y, Dulla D, Nega B. Prevalence and factors affecting disclosure of HIV status among pregnant women attending antenatal care in Addis Ababa public health centres: a cross sectional survey. Obstet Gynecol Int J. 2019;10(4):317-24.
27
[28] Boampong-Konam KA. Barriers to Disclosure of HIV Positive Status to Sexual Partner (S) In the Central Region, Ghana (Doctoral dissertation, University of Ghana).2015.
28
[29] Oseni OE, Okafor IP, Sekoni AO. Issues surrounding HIV status disclosure: Experiences of seropositive women in Lagos, Nigeria. International journal of preventive medicine. 2017;8. doi: 10.4103/ijpvm.IJPVM_136_15.
29
[30] Colombe S, Beard J, Mtenga B, Lutonja P, Mngara J, Claudia J, et al. HIV-seroconversion among HIV-1 serodiscordant married couples in Tanzania: a cohort study. BMC infectious diseases. 2019;19(1):1-8. https://doi.org/10.1186/s12879-019-4151-8
30
[31] Wei C, Lim SH, Guadamuz TE, Koe S. HIV disclosure and sexual transmission behaviors among an Internet sample of HIV-positive men who have sex with men in Asia: implications for prevention with positives. AIDS and Behavior. 2012;16(7):1970-8. https://doi.org/10.1007/s10461-011-0105-x.
31
[32] Nordberg B, Gabriel EE, Were E, Kaguiri E, Ekström AM, Kågesten A, et al. Social concerns related to HIV status disclosure and participation in the prevention of mother-to-child transmission of HIV care among pregnant women in Kenya. BMC pregnancy and childbirth. 2020;20:1-9. https://doi.org/10.1186/s12884-020-02907-x.
32
ORIGINAL_ARTICLE
The Long Term Ability of Heliotherapy in Improving the Quality of Life and Alleviating Disease Activity in Patients with Psoriasis
Background and aim: Psoriasis is a chronic, multisystem inflammatory skin disease that adversely affects the quality of life. It is crucial to control disease activity and use all of the feasible therapeutic modalities to preserve the quality of life as much as possible. Heliotherapy uses natural sunlight in improving different skin conditions and represents the form of phototherapy. This study aims to assess the long-term effects of heliotherapy and compare it with outcomes of other research.Materials and methods: A total of 27 patients participated in an observational study of 2-week heliotherapy conducted at the seaside of Montenegro. Disease activity and the quality of life were measured using PASI and DLQI scores at three points of time: before starting heliotherapy, after two weeks, and three months of heliotherapy.Results: Mean PASI score before the treatment was 11,31. The results revealed a decrease in PASI values after 14 days of therapy by 30%, as well as a statistically significant decrease in PASI values after three months of therapy by 29% (p <0.001). Additionally, the present study has shown a reduction in DLQI score by 41.7% (p <0.001) comparing to baseline. However, three months after the heliotherapy DLQI score was reduced by 8,33% (p=0.006) comparing to the baseline, indicating that the score was returning to the pre-therapy values.Conclusion: To conclude, two-week heliotherapy has shown satisfying, long-lasting effects in reducing PASI score and ameliorating disease severity, but it did not show beneficial effects in improving the quality of life in the long term.
http://www.ijsrdms.com/article_130519_30d9f540ff2807a9dc006d8babb6868f.pdf
2021-06-01
61
65
10.30485/ijsrdms.2021.278380.1140
Heliotherapy
Psoriasis
Quality of Life
Milena
Djurovic
djurovicdrmilena@gmail.com
1
Clinical Center of Montenegro, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
AUTHOR
Agima
Ljaljevic
agima.ljaljevic@ijzcg.me
2
Institute for Public Health, School of Medicine, University of Montenegro, Podgorica, Montenegro
AUTHOR
Milica
Djurovic
m.djurovic19@gmail.com
3
Department of Dermatology, School of Medicine, University of Montenegro, Podgorica, Montenegro
LEAD_AUTHOR
Milos
Bojic
milos.bojic1101@gmail.com
4
Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
AUTHOR
[1] Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377-85. https://doi.org/10.1038/jid.2012.339.
1
[2] Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clinics in dermatology. 2018;36(1):21-8. https://doi.org/10.1016/j.clindermatol.2017.09.005.
2
[3] Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633-9. https://doi.org/10.1159/000455840.
3
[4] Mathew C, Sridharan R, Sudhamani B. A study of the association of psoriasis with metabolic syndrome from a tertiary care centre in Kerala, South India. IP Indian J Clin Exp Dermatol 2021;7(1):18-23.
4
[5] Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinical reviews in allergy & immunology. 2018;55(3):379-90. https://doi.org/10.1007/s12016-018-8702-3
5
[6] Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi:10.1101/cshperspect.a015354
6
[7] De Korte J, Mombers FM, Bos JD, Sprangers MA. Quality of life in patients with psoriasis: a systematic literature review. InJournal of Investigative Dermatology Symposium Proceedings 2004;9(2):140-147. https://doi.org/10.1046/j.1087-0024.2003.09110.x.
7
[8] Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. Journal of psychosomatic research. 2019;124:109780. https://doi.org/10.1016/j.jpsychores.2019.109780.
8
[9] González-Parra S, Daudén E. Psoriasis and depression: the role of inflammation. Actas dermo-sifiliograficas. 2019;110 (1):12-9. https://doi.org/10.1016/j.ad.2018.05.009.
9
[10] Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate‐to‐severe psoriasis: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2017;31(2):213-20. https://doi.org/10.1111/jdv.14007.
10
[11] Bruins FM, Bronckers IM, Groenewoud HM, van de Kerkhof PC, De Jong EM, Seyger MM. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA dermatology. 2020;156(1):72-8. doi:10.1001/jamadermatol.2019.3717.
11
[12] Kwan Z, Bong YB, Tan LL, Lim SX, Yong AS, Ch’ng CC, et al. Determinants of quality of life and psychological status in adults with psoriasis. Archives of dermatological research. 2018;310(5):443-51. https://doi.org/10.1007/s00403-018-1832-x
12
[13] Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61(2 Suppl):11-21.
13
[14] Karppinen T, Ylianttila L, Kautiainen H, Reunala T, Snellman E. Empowering heliotherapy improves clinical outcome and quality of life of psoriasis and atopic dermatitis patients. Acta dermato-venereologica. 2015;95(5):579-82.
14
[15] Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal Torjesen P, Hagve TA, et al. Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology. 2009;23(10):1133-40.https://doi.org/10.1111/j.1468-3083.2009.03245.x.
15
[16] Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clinical and experimental dermatology. 1994;19(3):210-6. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x.
16
[17] Shankar V, Ghosh S, Ghosh K, Chaudhuri U. PASI and PQOL-12 score in psoriasis: Is there any correlation?. Indian journal of dermatology. 2011;56(3):287. doi: 10.4103/0019-5154.82482.
17
[18] Wahl AK, Langeland E, Larsen MH, Robinson HS, Osborne RH, Polesie AL. Positive changes in self-management and disease severity following climate therapy in people with psoriasis. Acta dermato-venereologica. 2015;95(3):317-21. DOI: http://dx.doi.org/10.2340/00015555-1939.
18
[19] Harari M, Novack L, Barth J, David M, Friger M, Moses SW. The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea. International journal of dermatology. 2007;46(10):1087-91. https://doi.org/10.1111/j.1365-4632.2007.03278.x.
19
[20] Kopel E, Levi A, Harari M, Ruzicka T, Ingber A. Effect of the Dead Sea climatotherapy for psoriasis on quality of life. Isr Med Assoc J 2013; 15: 99–102.
20
[21] Emmanuel T, Lybæk D, Johansen C, Iversen L. Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study. Front Med (Lausanne). 2020;7:83. Published 2020 Mar 18. doi:10.3389/fmed.2020.00083
21
[22] Snellman E, Lauharanta J, Reunanen A, Jansén CT, Jyrkinen-Pakkasvirta T, Kallio M, et al. Effect of heliotherapy on skin and joint symptoms in psoriasis: a 6-month follow-up study. Br J Dermatol. 1993 Feb;128(2):172-7. doi: 10.1111/j.1365-2133.1993.tb15147.
22
[23] Wahl A, Mork C, Cooper B, Padilla G. No long-term changes in psoriasis severity and quality of life following climate therapy. J Am Acad Dermatol 2005; 52: 699–701.
23
[24] Noronha-Neta MI, Picciani BLS, Niemeyer-Corbellini JP, Ramos-E-Silva M, Soares FA, Carneiro S. Quantification of histopathological changes in patients with psoriasis before and after phototherapy. Photodermatol Photoimmunol Photomed. 2019 Sep;35(5):354-359. doi: 10.1111/phpp.12492.
24
[25] Mørk C, Wahl A. Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol. 2002 Aug;47(2):314-6. doi: 10.1016/s0190-9622(02)00066-x.
25
[26] Trøstrup H, Riis PT, Heidenheim M, Bryld LE, Jemec GB. Long-term evaluation of climatotherapy for psoriasis. Dermatol Ther. 2020 May;33(3):e13432. doi: 10.1111/dth.13432.
26
[27] Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017 Aug;28(5):374-383. doi: 10.1080/09546634.2016.1254331.
27
ORIGINAL_ARTICLE
The Use of Herbal Medicines in Pregnancy: A Cross-sectional Analytic Study
Background and aim: The use of complementary and alternative medicine is increasing worldwide; Some of the medications, including native herbs, are taken just before conception and in all trimesters and may be risky to the conceptus. The extent and the factors affecting usage vary and have not been adequately studied. The study aimed to determine the prevalence and factors associated with Herbal medicine use among pregnant and recently pregnant women.Materials and methods: Magnitude of use of Herbal medication, the sociodemographic, other associated factors and, the various types of the medications used were evaluated. It was a cross-sectional study. An unvalidated semi-structured, interviewer-assisted questionnaire was used to obtain information. Consenting current or recently pregnant women attending public tertiary and private specialist hospitals were included in the study, while unconscious, severely sick women were excluded; 120 responded and were consecutively recruited. Stata version13 statistical software was used for data analysis. The prevalence, type of Herbal medicines used, associated factors, and pregnancy outcomes were measured. A two-sided (5% significance level) test of significance at a 95% confidence level was adopted. The study duration was three months, from October to December 2020.Results: The rate of usage of Herbal medication in the index pregnancy was 22.5%; bitter leaf was the highest 6 (22.2%), followed by Herbal concoctions (agbo) and moringa- 18.5% and 11.1%, respectively. Malaria in pregnancy was the commonest indication (18.5%). Usage was lower amongst high parity patients; use is the same across sociodemographic strata. Family and friends were the primary sources of information (40.7%).Conclusion: The use of natural or Herbal products in pregnancy was relatively common in the study. The medications were used mainly for the presumed diagnosis of malaria. Therefore, there is a need for health personnel to be actively involved in the education of pregnant women, especially in the early trimester and lower parity, about Herbal drug use and the inherent dangers.
http://www.ijsrdms.com/article_130778_b43daebc451c8305e64518abaa73296b.pdf
2021-06-01
66
72
10.30485/ijsrdms.2021.280771.1144
herbal drugs
Pregnancy
Prevalence
Onwusulu
Nnaemeka
onwusulud@yahoo.com
1
Department of Obstertics and Gynaecology, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
LEAD_AUTHOR
Nnamani
Phyllis
cp.nnamani@unizik.edu.ng
2
Department of Family Medicine, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
AUTHOR
Offor
Chinaza
confidenceoffor36@gmail.com
3
Department of Family Medicine, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
AUTHOR
[1] Qi Z. Who traditional medicine strategy. 2014-2023. Geneva: World Health Organization. 2013.
1
[2] Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bulletin of the World Health Organization. 2008;86:594-9. doi:10.2471/BLT.07.042820.
2
[3] World Health Organization (WHO). Herbal medicine research and global health: an ethical analysis. WHO. World Health Organization; 2011.
3
[4] Laelago T. Herbal medicine use during pregnancy: benefits and untoward effects. Herbal medicine. 2018.
4
[5] John LJ, Shantakumari N. Herbal medicines use during pregnancy: a review from the Middle East. Oman medical journal. 2015;30(4):229-236. doi: 10.5001/omj.2015.48.
5
[6] Mothupi MC. Use of herbal medicine during pregnancy among women with access to public healthcare in Nairobi, Kenya: a cross-sectional survey. BMC complementary and alternative medicine. 2014;14(1):1-8. https://doi.org/10.1186/1472-6882-14-432.
6
[7] Jaradat N, Adawi D. Use of herbal medicines during pregnancy in a group of Palestinian women. Journal of ethnopharmacology. 2013;150(1):79-84. https://doi.org/10.1016/j.jep.2013.07.041.
7
[8] Adane F, Seyoum G, Alamneh YM, Abie W, Desta M, Sisay B. Herbal medicine use and predictors among pregnant women attending antenatal care in Ethiopia: a systematic review and meta-analysis. BMC pregnancy and childbirth. 2020;20(1):1-1. https://doi.org/10.1186/s12884-020-2856-8.
8
[9] Ologe MO, Aboyeji AP, Ijaiya MA, Adesina KT, Adewara AA, Olarinoye JK. Herbal use among pregnant mothers in Ilorin, Kwra State, Nigeria. Journal of Obstetrics and Gynaecology. 2008;28(7):720-1. https://doi.org/10.1080/01443610802461912.
9
[10] Fakeye TO, Adisa R, Musa IE. Attitude and use of herbal medicines among pregnant women in Nigeria. BMC Complementary and alternative medicine. 2009;9(1):1-7. https://doi.org/10.1186/1472-6882-9-53.
10
[11] Duru CB, Uwakwe KA, Chinomnso NC, Mbachi II, Diwe KC, Agunwa CC, et al. Socio-demographic determinants of herbal medicine use in pregnancy among Nigerian women attending clinics in a tertiary Hospital in Imo State, south-east, Nigeria. Am J Med Stud. 2016;4(1):1-0. DOI:10.12691/ajms-4-1-1.
11
[12] Laelago T, Yohannes T, Lemango F. Prevalence of herbal medicine use and associated factors among pregnant women attending antenatal care at public health facilities in Hossana Town, Southern Ethiopia: facility based cross sectional study. Archives of Public Health. 2016;74(1):1-8. https://doi.org/10.1186/s13690-016-0118-z.
12
[13] Balbontín YM, Stewart D, Shetty A, Fitton CA, McLay JS. Herbal medicinal product use during pregnancy and the postnatal period: a systematic review. Obstetrics and gynecology. 2019;133(5):920-932. doi: 10.1097/AOG.0000000000003217.
13
[14] Forster DA, Denning A, Wills G, Bolger M, McCarthy E. Herbal medicine use during pregnancy in a group of Australian women. BMC pregnancy and childbirth. 2006;6(1):1-9. https://doi.org/10.1186/1471-2393-6-21.
14
[15] Tamuno I, Omole-Ohonsi A, Fadare J. Use of herbal medicine among pregnant women attending a tertiary hospital in Northern Nigeria. The Internet Journal of Gynecology and Obstetrics. 2011;15(2).
15
[16] Tabatabaee M. Use of herbal medicine among pregnant women referring to Valiasr Hospital in Kazeroon, Fars, South of Iran. J Med Plants. 2011;10(37):96–108.
16
[17] Bayisa B, Tatiparthi R, Mulisa E. Use of herbal medicine among pregnant women on antenatal care at Nekemte Hospital, Western Ethiopia. Jundishapur journal of natural pharmaceutical products. 2014;9(4): e17368.
17
[18] Nyeko R, Tumwesigye NM, Halage AA. Prevalence and factors associated with use of herbal medicines during pregnancy among women attending postnatal clinics in Gulu district, Northern Uganda. BMC pregnancy and childbirth. 2016;16(1):1-2. https://doi.org/10.1186/s12884-016-1095-5.
18
[19] Kennedy DA, Lupattelli A, Koren G, Nordeng H. Herbal medicine use in pregnancy: results of a multinational study. BMC complementary and alternative medicine. 2013;13(1):1-0. https://doi.org/10.1186/1472-6882-13-355.
19
[20] Heitmann K, Nordeng H, Holst L. Safety of ginger use in pregnancy: results from a large population-based cohort study. European journal of clinical pharmacology. 2013;69(2):269-77. https://doi.org/10.1007/s00228-012-1331-5.
20
[21] Kekana LS, Sebitloane MH. Ingestion of herbal medication during pregnancy and adverse perinatal outcomes. South African Journal of Obstetrics and Gynaecology. 2020;26(2):71-5. https://doi.org/10.7196/SAJOG.2020.v26i2.1615.
21
[22] Mekuria AB, Erku DA, Gebresillassie BM, Birru EM, Tizazu B, Ahmedin A. Prevalence and associated factors of herbal medicine use among pregnant women on antenatal care follow-up at University of Gondar referral and teaching hospital, Ethiopia: a cross-sectional study. BMC complementary and alternative medicine. 2017;17(1):1-7. https://doi.org/10.1186/s12906-017-1608-4.
22
ORIGINAL_ARTICLE
Epidemiology of Cleft Lip and Palate in Nigeria: A Data-Based Study
Background and aim: Prevalence of cleft lip and palate varies across geographical location, races, and ethnic groups. The global prevalence is 1 per 700 live births. We aim to establish the prevalence, socio-demographic characteristics of patients with an orofacial cleft, and associated deformities in our locality.Materials and methods: This was a retrospective study of all the patients with cleft lip (CL), cleft palate (CP), or cleft lip/palate (CLP) managed over 12 years (2009 to 2020). A uniform Smile Train® structured interviewer-administered questionnaire completed by the Surgeons was used to obtain relevant information. Data were analyzed using SPSS version 23.Results: A total of 280 patients were managed for cleft lip and palate deformities during this period. The estimated total live births during the period were 232,168; a prevalence rate of 0.8 per 1000 live births was thus calculated. The most common type of cleft deformity in our study is CLP (61.4%), followed by isolated CP (20.7%) and then CL (17.9%). CLP was shown to be more common among males (66.1%). However, isolated CP and CL were more common among females at 67.2% and 56%. The most common associated anomalies were speech (52.8%) and growth retardation (9.6%). The least common was limb anomalies (0.7%).Conclusion: Our study has generated new knowledge of the epidemiological distribution of orofacial cleft deformities in our subregion made possible by the Smile Train® database. It will enable more comprehensive management of orofacial clefts.
http://www.ijsrdms.com/article_130818_7c4af87fff7f05c495477631fd26edb2.pdf
2021-06-01
73
77
10.30485/ijsrdms.2021.278259.1137
Cleft lip
Cleft palate
Congenital anomalies
Epidemiology
Titus
Chukwuanukwu
to.chukwuanukwu@unizik.edu.ng
1
Department of Surgery, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi, Nigeria
LEAD_AUTHOR
Evaristus
Afiadigwe
ea.afiadigwe@unizik.edu.ng
2
Department of Ear, Nose and Throat (ENT), Faculty of Medicine, Nnamdi Azikiwe University, Nnewi, Nigeria
AUTHOR
Akunne
Apakama
akunneapakama@yahoo.com
3
Department of Ophthalmology, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi, Nigeria
AUTHOR
Rebecca
Chukwuanukwu
rc.chukwuanukwu@unizik.edu.ng
4
Department of Medical Laboratory Sciences, Faculty of Health Sciences, Nnamdi Azikiwe University, Nnewi, Nigeria
AUTHOR
Ezekiel
Uchechukwu Nwankwo
ucnwankwo3@gmail.com
5
Department of Surgery, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi, Nigeria
AUTHOR
Chinedu
Ilokanuno
cn.ilokanuno@unizik.edu.ng
6
Department of Surgery, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi, Nigeria
AUTHOR
[1] Kianifar H, Hasanzadeh N, Jahanbin A, Ezzati A, Kianifar H. Cleft lip and palate: a 30-year epidemiologic study in north-east of Iran. Iranian journal of otorhinolaryngology. 2015;27(78):35.
1
[2] Karthik L, Kumar G, Keswani T, Bhattacharyya A, Chandar SS, Rao KB. Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PloS one. 2014;9(3):e90972. https://doi.org/10.1371/journal.pone.0090972.
2
[3] Aldhorae KA, Böhmer AC, Ludwig KU, Esmail AH, Al-Hebshi NN, Lippke B. Nonsyndromic cleft lip with or without cleft palate in arab populations: Genetic analysis of 15 risk loci in a novel case–control sample recruited in Yemen. Birth Defects Research Part A: Clinical and Molecular Teratology. 2014;100(4):307-13. https://doi.org/10.1002/bdra.23221.
3
[4] Bekele KK, Ekanem PE, Meberate B. Anatomical patterns of cleft lip and palate deformities among neonates in Mekelle, Tigray, Ethiopia; implication of environmental impact. BMC pediatrics. 2019;19(1):1-7. https://doi.org/10.1186/s12887-019-1624-2.
4
[5] Praveen Kumar PS, Dhull KS, Lakshmikantha G, Singh N. Incidence and Demographic Patterns of Orofacial Clefts in Mysuru, Karnataka, India: A Hospital-based Study. International journal of clinical pediatric dentistry. 2018;11(5):371-374. doi: 10.5005/jp-journals-10005-1542.
5
[6] Conway JC, Taub PJ, Kling R, Oberoi K, Doucette J, Jabs EW. Ten-year experience of more than 35,000 orofacial clefts in Africa. BMC pediatrics. 2015;15(1):1-9. https://doi.org/10.1186/s12887-015-0328-5.
6
[7] Butali A, Adeyemo WL, Mossey PA, Olasoji HO, Onah II, Adebola A, et al. Prevalence of orofacial clefts in Nigeria. The Cleft Palate-Craniofacial Journal. 2014;51(3):320-5. https://doi.org/10.1597/12-135.
7
[8] Abulezz TA. Cleft lip and palate: An experience of a developing center in egypt. Journal of Craniofacial Surgery. 2017;28(8):e731-4. https://doi.org/10.1097/SCS.0000000000003870.
8
[9] Worley ML, Patel KG, Kilpatrick LA. Cleft L ip and P alate Cleft lip Cleft palate Craniofacial malformations Nasoalveolar molding. Clin Perinatol. 2018;45(4):661-678. doi:10.1016/j.clp.2018.07.006.
9
[10] Luiza A, Gois DN, Santos JA, Oliveira RL, Silva LC. A descriptive epidemiology study of oral cleft in sergipe, Brazil. International archives of otorhinolaryngology. 2013;17(4):390-4. https://doi.org/10.1055/s-0033-1352502.
10
[11] Volk AS, Davis MJ, Desai P, Hollier LH. The history and mission of smile train, a global cleft charity. Oral and Maxillofacial Surgery Clinics. 2020;32(3):481-8. https://doi.org/10.1016/j.coms.2020.04.010.
11
[12] Noorollahian M, Nematy M, Dolatian A, Ghesmati H, Akhlaghi S, Khademi GR. Cleft lip and palate and related factors: A 10 years study in university hospitalised patients at Mashhad—Iran. African journal of paediatric surgery: AJPS. 2015;12(4):286-290. doi: 10.4103/0189-6725.172576.
12
[13] Hoch MJ, Patel SH, Jethanamest D, Win W, Fatterpekar GM, Roland JT, et al. Head and neck MRI findings in CHARGE syndrome. American Journal of Neuroradiology. 2017;38(12):2357-63. https://doi.org/10.3174/ajnr.A5297.
13
[14] Diko S, Sheeder J, Guiahi M, Nacht A, Reeves S, Connell KA, et al. Identification of obstetric anal sphincter injuries (OASIs) and other lacerations: a national survey of nurse-midwives. International urogynecology journal. 2020:1-9.
14
[15] 2013 Nigeria Demographic and Health Survey (NDHS): South East. Accessed January 17, 2021. www.population.gov.ng.
15
[16] Iregbulem LM. The incidence of cleft lip and palate in Nigeria. The Cleft palate journal. 1982;19(3):201-5.
16
[17] Onah II, Okoye CP, Bala E. Early cleft lip and palate repair: Experience of the National Orthopedic Hospital Enugu, Southeast Nigeria. Journal of Cleft Lip Palate and Craniofacial Anomalies. 2019;6(2):99-103. DOI: 10.4103/jclpca.jclpca_26_18.
17
[18] Obuekwe ON, Akapata O. Pattern of cleft lip and palate in Benin City, Nigeria.2004;50(5).
18
[19] Ajike SO, Adebola RA, Efunkoya A, Adeoye J, Akitoye O, Veror N. Epidemiology of adult cleft patients in North-western Nigeria: our experience. Annals of African medicine. 2013;12(1):11-15. DOI: 10.4103/1596-3519.108243.
19
[20] Dvivedi J, Dvivedi S. A clinical and demographic profile of the cleft lip and palate in Sub-Himalayan India: A hospital-based study. Indian journal of plastic surgery: official publication of the Association of Plastic Surgeons of India. 2012;45(1):115. doi: 10.4103/0970-0358.96602.
20
[21] Eshete M, Gravenm PE, Topstad T, Befikadu S. The incidence of cleft lip and palate in Addis Ababa, Ethiopia. Ethiopian medical journal. 2011;49(1):1-5.
21
[22] Mossey P, Little J. Epidemiology of Oral Clefts: An International Perspective. In: Wyszynski DF, Editor. Cleft Lip and Palate: From Origin to Treatment. Oxford University Press; 2012.
22
[23] Manyama M, Rolian C, Gilyoma J, Magori CC, Mjema K, Mazyala E, et al. An assessment of orofacial clefts in Tanzania. BMC Oral health. 2011;11(1):1-6. https://doi.org/10.1186/1472-6831-11-5.
23
[24] Setó-Salvia N, Stanier P. Genetics of cleft lip and/or cleft palate: association with other common anomalies. European journal of medical genetics. 2014;57(8):381-93. https://doi.org/10.1016/j.ejmg.2014.04.003.
24
[25] Fakhim SA, Shahidi N, Lotfi A. Prevalence of associated anomalies in cleft lip and/or palate patients. Iranian journal of otorhinolaryngology. 2016;28(85):135-139.
25
[26] Agbenorku P, Ansah S, Acheampong A, Sabbah D, Bankas D, Adu E, et al. Komfo anokye teaching hospital multidisciplinary cleft clinic. Journal of Craniofacial Surgery. 2011;22(2):532-6. doi: 10.1097/SCS.0b013e318207f462.
26
ORIGINAL_ARTICLE
Silico Functional Annotation and Molecular Characterization of an Uncharacterized Protein MBO_502153 of Mycobacterium Tuberculosis Variant Bovis
Background and aim: Bovine, zoonotic, and wildlife tuberculosis are caused by Mycobacterium Bovis, whose attenuated form is used in tuberculosis and cancer treatment. There are several proteins present in its genome considered as uncharacterized or hypothetical proteins. We aim to predict the structure and function of an uncharacterized protein present in the bacterial genome of this pathogenic bacteria, Mycobacterium Bovis, by using several bioinformatics tools.Materials and methods: Using in silico techniques, the secondary and tertiary structures of the selected uncharacterized proteins were predicted and further validated. Bioinformatics tools were used to explore physicochemical characteristics, homologous proteins, the active site, and the protein-protein interactions.Results: By in silico study, we found that though the bacterium is a pathogenic microorganism, its uncharacterized protein MBO_502153 is non–virulent. This protein is a metabolism molecule. As the protein does not contain any kind of signal peptide, it is not a secretory protein. The uncharacterized protein MBO_502153 also does not involve any non-classical secretory pathway.Conclusion: It can be concluded that the purposeful annotation of uncharacterized supermolecule showed some chemical activities, particularly degradation of the environmental waste product 4-chlorobenzoate and xenobiotics and synthesis of polyhydroxyalkanoate (PHA), which play an important role in environmental biodegradability and biocompatibility.
http://www.ijsrdms.com/article_132175_0739fdb3844d27632e23fadaa6d193aa.pdf
2021-06-01
78
85
10.30485/ijsrdms.2021.287932.1160
MBO502153
Mycobacterium bovis
xenobiotics
Polyhydroxyalkanoates
Tarhima
Jerin
tarhimajahan0093@gmail.com
1
Department of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail 1902, Bangladesh
AUTHOR
Nahid
Sharmin
nahidsharmin@du.ac.bd
2
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh
AUTHOR
Sheikh
Raihan
sheikhzahir@du.ac.bd
3
Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh
LEAD_AUTHOR
[1] Rodriguez-Morales AJ, Castañeda-Hernández DM. Bacteria: Mycobacterium bovis. Encyclopedia of Food Safety. 2014: 468-475. DOI:http://dx.doi.org/10.1016/B978-0-12-378612-8.00103-7.
1
[2] Moda G, Daborn CJ, Grange JM, Cosivi O. The zoonotic importance of Mycobacterium bovis. Tubercle and Lung Disease. 1996;77(2):103-8. https://doi.org/10.1016/S0962-8479(96)90022-2.
2
[3] Organization WH. Report of the WHO Meeting on Zoonotic Tuberculosis (Mycobacterium bovis, Geneva, 15 November 1993. World Health Organization; 1993. DOI: https://doi.org/10.1016/s0962-8479(96)90022-2.
3
[4] Hoft DF, Gheorghiu M. Mucosal immunity induced by oral administration of bacille Calmette–Guérin. Mucosal vaccines, Elsevier; 1996, p. 269–79. DOI: https://doi.org/10.1016/B978-012410580-5/50021-2.
4
[5] Meije Y, Martínez-Montauti J, Caylà JA, Loureiro J, Ortega L, Clemente M, et al. Healthcare-Associated Mycobacterium bovis–Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation. Clinical Infectious Diseases. 2017;65(7):1136-43. https://doi.org/10.1093/cid/cix496.
5
[6] Nimrod G, Schushan M, Steinberg DM, Ben-Tal N. Detection of functionally important regions in “hypothetical proteins” of known structure. Structure. 2008;16(12):1755-63. https://doi.org/10.1016/j.str.2008.10.017.
6
[7] Chaudhry GR, Chapalamadugu S. Biodegradation of halogenated organic compounds. Microbiological reviews. 1991;55(1):59-79. https://doi.org/10.1128/mr.55.1.59-79.1991.
7
[8] Furukawa K, Simon JR, Chakrabarty AM. Common induction and regulation of biphenyl, xylene/toluene, and salicylate catabolism in Pseudomonas paucimobilis. Journal of Bacteriology. 1983;154(3):1356-62. https://doi.org/10.1128/jb.154.3.1356-1362.1983.
8
[9] Margesin R, Labbe D, Schinner F, Greer CW, Whyte LG. Characterization of hydrocarbon-degrading microbial populations in contaminated and pristine alpine soils. Applied and Environmental Microbiology. 2003;69(6):3085-92. https://doi.org/10.1128/AEM.69.6.3085-3092.2003.
9
[10] Kovalcik A, Obruca S, Fritz I, Marova I. Polyhydroxyalkanoates: their importance and future. BioResources. 2019;14(2):2468-71.
10
[11] Steinbüchel A. Recent advances in the knowledge of the metabolism of bacterial polyhydroxyalkanoic acids and potential impacts on the production of biodegradable thermoplastics. Acta biotechnologica. 1991;11(5):419-27. https://doi.org/10.1002/abio.370110504.
11
[12]Muhammadi, Shabina, Afzal M, Hameed S. Bacterial polyhydroxyalkanoates-eco-friendly next generation plastic: production, biocompatibility, biodegradation, physical properties and applications. Green Chemistry Letters and Reviews. 2015;8(3-4):56-77. https://doi.org/10.1080/17518253.2015.1109715.
12
[13] Zinn M, Witholt B, Egli T. Occurrence, synthesis and medical application of bacterial polyhydroxyalkanoate. Advanced drug delivery reviews. 2001;53(1):5-21. https://doi.org/10.1016/S0169-409X(01)00218-6.
13
[14] Steinbüchel A, Lütke-Eversloh T. Metabolic engineering and pathway construction for biotechnological production of relevant polyhydroxyalkanoates in microorganisms. Biochemical engineering journal. 2003;16(2):81-96. https://doi.org/10.1016/S1369-703X(03)00036-6.
14
[15] Koller M, Maršálek L, de Sousa Dias MM, Braunegg G. Producing microbial polyhydroxyalkanoate (PHA) biopolyesters in a sustainable manner. New biotechnology. 2017;37:24-38. https://doi.org/10.1016/j.nbt.2016.05.001.
15
[16] Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 2003;31:3784–8. DOI: https://doi.org/10.1093/nar/gkg563.
16
[17] Guruprasad K, Reddy BB, Pandit MW. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Engineering, Design and Selection. 1990;4(2):155-61. https://doi.org/10.1093/protein/4.2.155.
17
[18] Barh D, Tiwari S, Jain N, Ali A, Santos AR, Misra AN, et al. In silico subtractive genomics for target identification in human bacterial pathogens. Drug Development Research. 2011;72(2):162-77. https://doi.org/10.1002/ddr.20413.
18
[19] Yu CS, Chen YC, Lu CH, Hwang JK. Prediction of protein subcellular localization. Proteins: Structure, Function, and Bioinformatics. 2006;64(3):643-51. https://doi.org/10.1002/prot.21018.
19
[20] Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics. 2010;26(13):1608-15. https://doi.org/10.1093/bioinformatics/btq249.
20
[21] Bhasin M, Garg A, Raghava GP. PSLpred: prediction of subcellular localization of bacterial proteins. Bioinformatics. 2005;21(10):2522-4. https://doi.org/10.1093/bioinformatics/bti309.
21
[22] Imai K, Asakawa N, Tsuji T, Akazawa F, Ino A, Sonoyama M, et al. SOSUI-GramN: high performance prediction for sub-cellular localization of proteins in gram-negative bacteria. Bioinformation. 2008;2(9):417. doi: 10.6026/97320630002417.
22
[23] Möller S, Croning MD, Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics. 2001;17(7):646-53. https://doi.org/10.1093/bioinformatics/17.7.646.
23
[24] Tusnady GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics. 2001;17(9):849-50. https://doi.org/10.1093/bioinformatics/17.9.849.
24
[25] Dobson L, Reményi I, Tusnády GE. CCTOP: a Consensus Constrained TOPology prediction web server. Nucleic acids research. 2015;43(W1):W408-12. https://doi.org/10.1093/nar/gkv451.
25
[26] von Heijne PT. G. et al SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat. Methods.2011;8:785-6. DOI: https://doi.org/10.1038/nmeth.1701.
26
[27] Bendtsen JD, Kiemer L, Fausbøll A, Brunak S. Non-classical protein secretion in bacteria. BMC microbiology. 2005;5(1):1-3. https://doi.org/10.1186/1471-2180-5-58.
27
[28] Boeckmann B, Bairoch A, Apweiler R. Blatter 2. MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O’Donovan C, Phan I, Pilbout S, Schneider M (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res.;31:365-70. DOI: https://doi.org/10.1093/nar/gkg095.
28
[29] Finn RD, Bateman A, Clements J. Co ggill P., Eberhardt RY, Eddy SR et al. Pfam: the protein families database. Nucleic Acids Res 2014;42:D222–30. DOI: https://doi.org/10.1093/nar/gkt1223.
29
[30] Wilson D, Madera M, Vogel C, Chothia C, Gough J. The SUPERFAMILY database in 2007: families and functions. Nucleic Acids Res 2007;35:D308–13. DOI: https://doi.org/10.1093/nar/gkl910.
30
[31] Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science. 1991:1162-4.
31
[32] Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, et al. InterPro: the integrative protein signature database. Nucleic acids research. 2009;37(suppl_1):D211-5. https://doi.org/10.1093/nar/gkn785.
32
[33] Shen HB, Chou KC. Predicting protein fold pattern with functional domain and sequential evolution information. Journal of Theoretical Biology. 2009;256(3):441-6. https://doi.org/10.1016/j.jtbi.2008.10.007.
33
[34] Garg A, Gupta D. VirulentPred: a SVM based prediction method for virulent proteins in bacterial pathogens. BMC bioinformatics. 2008;9(1):1-2. https://doi.org/10.1186/1471-2105-9-62.
34
[35] Dillon SC, Bateman A. The Hotdog fold: wrapping up a superfamily of thioesterases and dehydratases. BMC bioinformatics. 2004;5(1):1-4. https://doi.org/10.1186/1471-2105-5-109.
35
[36] Kokkinidis M, Glykos NM, Fadouloglou VE. Protein flexibility and enzymatic catalysis. Advances in protein chemistry and structural biology. 2012;87:181-218. https://doi.org/10.1016/B978-0-12-398312-1.00007-X.
36
[37] Neill SD, Pollock JM, Bryson DB, Hanna J. Pathogenesis of Mycobacterium bovis infection in cattle. Veterinary microbiology. 1994;40(1-2):41-52. https://doi.org/10.1016/0378-1135(94)90045-0.
37
[38] Hooda V, babu Gundala P, Chinthala P. Sequence analysis and homology modeling of peroxidase from Medicago sativa. Bioinformation. 2012;8(20):974-979. doi: 10.6026/97320630008974.
38
[39] Fukui T, Shiomi N, Doi Y. Expression and characterization of (R)-specific enoyl coenzyme A hydratase involved in polyhydroxyalkanoate biosynthesis by Aeromonas caviae. Journal of Bacteriology. 1998;180(3):667-73. https://doi.org/10.1128/JB.180.3.667-673.1998.
39
ORIGINAL_ARTICLE
Multidetector-Row Computed Tomography and Colour Doppler Imaging in the Evaluation of Patients with Extrahepatic Portal Hypertension: A Prospective Study
Background and aims: Evaluating patients of extrahepatic portal hypertension with Colour Doppler and MDCT to study the morphology of splenoportal axis, determining the site of obstruction, the anatomy of portosystemic collaterals, any associated vascular aneurysms, and features of portal biliopathy.Materials and methods: We studied 45 patients (aged 6-55 years) with clinical features of portal hypertension with no identifiable hepatic cause or extrahepatic portal venous occlusion on sonography. All cases underwent Doppler ultrasound and MDCT. The data was compiled and analyzed. A comparative evaluation of Doppler imaging and MDCT was performed with the help of Cohen's kappa test to assess the agreement between the two modalities.Results: MDCT provides better details about the morphology of the splenoportal axis, the site, and cause of block, as well as the extent and distribution of collateral groups. Colour Doppler has an advantage over MDCT in determining the direction and pattern of blood flow within the splenoportal axis, various collaterals, and spontaneous shunts, along with a better depiction of features of portal biliopathy. Colour Doppler is inadequate in the visualization of gastroesophageal and retroperitoneal varices. Identification of spontaneous spleno-adreno-renal and gastrorenal shunts is achieved with the high agreement between Colour Doppler and MDCT.Conclusion: MDCT should be preferred for preoperative evaluation of patients being contemplated for shunt surgery. Colour Doppler imaging of portal biliopathy is sufficiently characteristic to avoid other invasive modalities. The two modalities provide complementary information in the evaluation of patients with extrahepatic portal hypertension.
http://www.ijsrdms.com/article_132657_e38e9f1d0c8124569c1847754e12e6be.pdf
2021-06-01
86
93
10.30485/ijsrdms.2021.285539.1153
Colour Doppler imaging
extrahepatic portal vein obstruction
multidetector-row computed Tomography
portosystemic collaterals
Asim
Rather
asimrather@yahoo.com
1
Department of Radiology, Sher-i-Kashmir Institute of Medical Sciences, Soura, India
AUTHOR
Gh Mohammad
Wani
mohammadwani86@gmail.com
2
Department of Radiology, Sher-i-Kashmir Institute of Medical Sciences, Soura, India
LEAD_AUTHOR
Irfan
Robbani
irfanrobbani@yahoo.com
3
Department of Radiology, Sher-i-Kashmir Institute of Medical Sciences, Soura, India
AUTHOR
[1] Dilawari JB, Chawla YK. Extrahepatic portal venous obstruction. Gut. 1988;29(4):554-5. doi: 10.1136/gut.29.4.554.
1
[2] Anand CS, Tandon BN, Nundy S. The causes, management and outcome of upper gastrointestinal haemorrhage in an Indian hospital. Journal of British Surgery. 1983;70(4):209-11. https://doi.org/10.1002/bjs.1800700407.
2
[3] Poddar U, Thapa BR, Rao KN, Singh K. Etiological spectrum of esophageal varices due to portal hypertension in Indian children: is it different from the West?. Journal of gastroenterology and hepatology. 2008;23(9):1354-7. https://doi.org/10.1111/j.1440-1746.2007.05102.x.
3
[4] WEBB LJ, SHERLOCK S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. QJM: An International Journal of Medicine. 1979;48(4):627-39. https://doi.org/10.1093/oxfordjournals.qjmed.a067598.
4
[5] Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. The American journal of medicine. 1992;92(2):173-82. https://doi.org/10.1016/0002-9343(92)90109-O.
5
[6] Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. Journal of hepatology. 2000;32(5):865-71. DOI:https://doi.org/10.1016/S0168-8278(00)80259-7.
6
[7] Witte CL, Brewer ML, Witte MH, Pond GB. Protean manifestations of pylethrombosis. A review of thirty-four patients. Annals of surgery. 1985;202(2):191. doi: 10.1097/00000658-198508000-00009.
7
[8] Thompson EN, SHERLOCK S. The aetiology of portal vein thrombosis with particular reference to the role of infection and exchange transfusion. QJM: An International Journal of Medicine. 1964;33(4):465-80.
8
[9] Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988 Apr 1;94(4):1063-9. https://doi.org/10.1016/0016-5085(88)90567-7.
9
[10] Lang R, Inbal A, Jutrin I, Ravid M. Recurrent venous thrombosis: the sole manifestation of an occult myeloproliferative disease. Israel journal of medical sciences. 1982;18(6):705-7.
10
[11] Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. Journal of cancer research and clinical oncology. 1998;124(7):397-400. https://doi.org/10.1007/s004320050189.
11
[12] Broe PJ, Conley CL, Cameron JL. Thrombosis of the portal vein following splenectomy for myeloid metaplasia. Surgery, gynecology & obstetrics. 1981;152(4):488-92.
12
[13] Eguchi A, Hashizume M, Kitano S, Tanoue K, Wada H, Sugimachi K. High rate of portal thrombosis after splenectomy in patients with esophageal varices and idiopathic portal hypertension. Archives of Surgery. 1991;126(6):752-5. doi:10.1001/archsurg.1991.01410300098015.
13
[14] Fujita F, Lyass S, Otsuka K, Giordano L. Portal vein thrombosis following splenectomy: identification of risk factors. The American surgeon. 2003;69(11):951.
14
[15] Rossi P, Passariello R, Simonetti G. Portal thrombosis: high incidence following splenectomy for portal hypertension. Gastrointestinal radiology. 1976;1(1):225-7. https://doi.org/10.1007/BF02256370.
15
[16] Poddar U, Thapa BR, Singh K. Band ligation plus sclerotherapy versus sclerotherapy alone in children with extrahepatic portal venous obstruction. Journal of clinical gastroenterology. 2005;39(7):626-9. doi: 10.1097/01.mcg.0000170765.36825.66.
16
[17] Achar S, Dutta HK, Gogoi RK. Extrahepatic portal vein obstruction in children: role of preoperative imaging. Journal of Indian Association of Pediatric Surgeons. 2017;22(3):144. doi: 10.4103/0971-9261.207634.
17
[18] Madrazo BL, Jafri SZ, Shirkhoda A, Roberts JL, Ellwood RA. Portosystemic collaterals: evaluation with color Doppler imaging and correlation with CT and MRI. InSeminars in interventional radiology 1990;7(03)-169-184. DOI: 10.1055/s-2008-1074606.
18
[19] De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K. Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR. American journal of roentgenology. 1995;165(5):1151-5. 10.2214/ajr.165.5.7572494.
19
[20] Arora NK, Lodha R, Gulati S, Gupta AK, Mathur P, Joshi MS, et al. Portai hypertension in North Indian children. The Indian Journal of Pediatrics. 1998;65(4):585-91. https://doi.org/10.1007/BF02730901.
20
[21] VALLA DC, Condat B, Lebrec D. Spectrum of portal vein thrombosis in the West. Journal of Gastroenterology and Hepatology. 2002;17:S224-7. https://doi.org/10.1046/j.1440-1746.17.s3.4.x.
21
[22] Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut. 2007;56(7):1001-8. http://dx.doi.org/10.1136/gut.2006.103606.
22
[23] Adaletli I, Bariş S, Gülşen G, Kurugoglu S, Kantarci F, Mihmanli I, et al. Comparison of color doppler US and CT portography in evaluating portal hypertension in children. Southern medical journal. 2012;105(1):6-10.
23
[24] El-Assaly H, Metwally LI, Azzam H, Seif-Elnasr MI. A comparative study of multi-detector CT portography versus endoscopy in evaluation of gastro-esophageal varices in portal hypertension patients. Egyptian Journal of Radiology and Nuclear Medicine. 2020;51(1):1-0. https://doi.org/10.1186/s43055-019-0117-5.
24
[25] Nićiforović D, Till V, Vučaj-Ćirilović V, Petrović K, Juković M, Hadnađev-Šimonji D, et al. The role of the color Doppler ultrasonography and computed tomography in estimation of portal hypertension. Srpski arhiv za celokupno lekarstvo. 2016;144(11-12):602-7. https://doi.org/10.2298/SARH1612602N.
25
ORIGINAL_ARTICLE
Complete Denture with Sectional-Tray Approach in a Microstomia Patient: A Case Report and Literature Review
Microstomia refers to any significant decrease in the size of the oral cavity. It can cause difficulty in the fabrication of dentures, and the result of this situation shows a significant decline in quality of life. This study describes a treatment method for preparing a complete denture in an edentulous patient with microstomia due to burns. The present study decided to employ a sectional tray and single unit denture considering the hygienic issue and prolonged durability. The major advantage of this scheme is reducing food impaction between different parts. Eventually, the patient was noticeably satisfied, and aesthetic and functional demands were provided.
http://www.ijsrdms.com/article_131441_0b828da476d8aa73b1feb08c0d944680.pdf
2021-06-01
94
100
10.30485/ijsrdms.2021.279477.1141
Dental impression technique
Denture
Microstomia
Fatemeh
Soleimani
fsoleimani@razi.tums.ac.ir
1
Dental Research Center, Dentistry Research Institute, Department of Prosthodontics, Alborz University of Medical Sciences, Alborz, Iran
AUTHOR
Negin
Yaghoobi
neginya1991@gmail.com
2
Dental Research Center, Dentistry Research Institute, Department of Prosthodontics, Tehran University of Medical Science, Tehran, Iran
AUTHOR
Somayeh
Niakan
drsomayehniakan@yahoo.com
3
Dental Research Center, Dentistry Research Institute, Department of Prosthodontics, Tehran University of Medical Science, Tehran, Iran
LEAD_AUTHOR
[1] Patil S, Raj AT, Sarode SC, Sarode GS, Menon RK, Bhandi S. Prosthetic rehabilitation of microstomia patients: a systematic review of published case reports and case series. J Contemp Dent Pract. 2019;20:508-15.
1
[2] Abou-Atme YS, Chedid N, Melis M, Zawawi KH. Clinical measurement of normal maximum mouth opening in children. CRANIO®. 2008;26(3):191-6. https://doi.org/10.1179/crn.2008.025.
2
[3] Cheng AC, Kwok-Seng L, Wee AG, Tee-Khin N. Prosthodontic management of edentulous patient with limited oral access using implant-supported prostheses: A clinical report. The Journal of prosthetic dentistry. 2006;96(1):1-6. https://doi.org/10.1016/j.prosdent.2006.04.010.
3
[4] Mulay S. Impression Techniques for Microstomia Patients: No longer Cumbersome - A Review. Int J Dent Oral health. Sci Forschen, Inc.; 2015;1(2):1-3. http:// doi.org/10.16966/2378-7090.109.
4
[5]. Bhushan K, Fernandes A, Sandhu PK. Restricted Mouth Opening And Its Preventive Therapy-A.2016;3(13):161-165.
5
[6] Tolle SL. Scleroderma: considerations for dental hygienists. International journal of dental hygiene. 2008;6(2):77-83. https://doi.org/10.1111/j.1601-5037.2008.00292.x.
6
[7] Dougherty ME, Warden GD. A thirty-year review of oral appliances used to manage microstomia, 1972 to 2002. The Journal of burn care & rehabilitation. 2003;24(6):418-31. https://doi.org/10.1097/01.BCR.0000095517.97355.98.
7
[8] Kumar B, Fernandes A, Sandhu PK. Restricted mouth opening and its definitive management: A literature review. Indian Journal of Dental Research. 2018;29(2):217.
8
[9] Kumar KA, Bhat V, Nair KC, Suresh R. Preliminary impression techniques for microstomia patients. The Journal of the Indian Prosthodontic Society. 2016;16(3):229-33. doi: 10.4103/0972-4052.186400.
9
[10] Silvestre-Rangil J, Martinez-Herrera M, Silvestre FJ. Manejo clínico odontológico del paciente con microstomia. Una revisión de la literatura y puesta al día. Journal of Oral Research. 2015;4(5):340-50. https://doi.org/10.17126/joralres.2015.065.
10
[11] Hegde C, Prasad K, Prasad A, Hegde R. Impression tray designs and techniques for complete dentures in cases of microstomia—A review. Journal of prosthodontic research. 2012;56(2):142-6. https://doi.org/10.1016/j.jpor.2011.04.001.
11
[12] Luebke RJ. Sectional impression tray for patients with constricted oral opening. Journal of Prosthetic Dentistry. 1984;52(1):135-7. DOI:https://doi.org/10.1016/0022-3913(84)90196-3.
12
[13] McCord JF, Tyson KW, Blair IS. A sectional complete denture for a patient with microstomia. The Journal of prosthetic dentistry. 1989;61(6):645-7. https://doi.org/10.1016/S0022-3913(89)80033-2.
13
[14] SAtpAthy A, GujjAri AK. Complete denture in a microstomia patient. Journal of clinical and diagnostic research: JCDR. 2015;9(5):ZD16.doi: 10.7860/JCDR/2015/12280.5910.
14
[15] Cheng AC, Wee AG, Shiu-Yin C, Tat-Keung L. Prosthodontic management of limited oral access after ablative tumor surgery: a clinical report. The Journal of prosthetic dentistry. 2000;84(3):269-73. https://doi.org/10.1067/mpr.2000.109490.
15
[16] Kumar CA, Jei JB, Murugesan K, Muthukumar B. A novel approach of rehabilitation of a microstomia patient with sectional hinged dentures. Journal of Interdisciplinary Dentistry. 2020;10(1):39-43. DOI: 10.4103/jid.jid_65_19.
16
[17] Kaira LS, Dabral E. Prosthetic management of microstomia with sectional denture. The Saudi Journal for Dental Research. 2014;5(2):93-7. https://doi.org/10.1016/j.sjdr.2014.01.003.
17
[18] Gauri M, Ramandeep D. Prosthodontic management of a completely edentulous patient with microstomia: a case report. The Journal of Indian Prosthodontic Society. 2013;13(3):338-42. https://doi.org/10.1007/s13191-013-0263-9.
18
[19] Kumar S, Arora A, Yadav R. Foldable denture: For microstomia patient. Case reports in dentistry. 2012. https://doi.org/10.1155/2012/757025.
19
[20] Geckili O, Cilingir A, Bilgin T. Impression procedures and construction of a sectional denture for a patient with microstomia: a clinical report. The Journal of prosthetic dentistry. 2006;96(6):387-90. https://doi.org/10.1016/j.prosdent.2006.10.008.
20
[21] Cura C, Cotert HS, User A. Fabrication of a sectional impression tray and sectional complete denture for a patient with microstomia and trismus: a clinical report. The Journal of prosthetic dentistry. 2003;89(6):540-3. https://doi.org/10.1016/S0022-3913(03)00179-3.
21
[22] Watanabe I, Tanaka Y, Ohkubo C, Miller AW. Application of cast magnetic attachments to sectional complete dentures for a patient with microstomia: A clinical report. The Journal of prosthetic dentistry. 2002;88(6):573-7. https://doi.org/10.1067/mpr.2002.130095.
22
[23] Colvenkar SS. Sectional impression tray and sectional denture for a microstomia patient. Journal of Prosthodontics: Implant, Esthetic and Reconstructive Dentistry. 2010;19(2):161-5. https://doi.org/10.1111/j.1532-849X.2009.00529.x.
23
[24] Saygılı S, Geckili O, Sulun T. Prosthetic rehabilitation of an edentulous patient with microstomia using both digital and conventional techniques: a clinical report. Journal of Prosthodontics. 2019;28(5):488-92. https://doi.org/10.1111/jopr.13061.
24
[25] Tayari O, Jaouadi J, Jemli S, Haloui H, Ben Rahma A. Prosthetic Rehabilitation on Edentulous Patients with Microstomia: About Three Cases. Case reports in dentistry. 2019. https://doi.org/10.1155/2019/9578083.
25
[26] Balakrishnan J, Anilkumar S, Gopalakrishnan S, VJ A, Nanukuttan SK, Unnikrishnan PT. MODIFICATION OF IMPRESSION PROCEDURES WITH THE USE OF CUSTOM SECTIONAL TRAYS FOR A MICROSTOMIA PATIENT–A CASE REPORT.2020;3(2):88-93.
26
[27] Tulunoglu I, Lee MH, Taifur ML, Tulunoglu O. Restoring masticatory function in a patient with severe microstomia using rapid prototyped mesh and a custom-made hinge and swing-lock prosthesis. The Journal of prosthetic dentistry. 2018;119(6):887-92. https://doi.org/10.1016/j.prosdent.2017.06.016.
27
[28] Givan DA, AuClair WA, Seidenfaden, CDT JC, Paiva J. Sectional impressions and simplified folding complete denture for severe microstomia. Journal of Prosthodontics: Implant, Esthetic and Reconstructive Dentistry. 2010;19(4):299-302. https://doi.org/10.1111/j.1532-849X.2009.00564.x.
28
[29] Jain V, Gowda EM, Prakash P, Udayshankar V. Microstomia: Difficult Proposition to Rehabilitate.2019;6(7):14-17.
29
[30] Dewan SK, Arora A, Sehgal M, Khullar A. Microstomia—a treatment challenge to a prosthodontist. Journal of clinical and diagnostic research: JCDR. 2015;9(4):ZD12. doi: 10.7860/JCDR/2015/12504.5787.
30
[31] Whitsitt JA, Battle LW. Technique for making flexible impression trays for the microstomic patient. The Journal of prosthetic dentistry. 1984;52(4):608-9. https://doi.org/10.1016/0022-3913(84)90359-7.
31
[32] Samet N, Tau S, Findler M, Susarla SM. Flexible, removable partial denture for a patient with systemic sclerosis (scleroderma) and microstomia: a clinical report and a three-year follow-up. General dentistry. 2007;55(6):548-51.
32
[33] Prashanti E, Jain N, Shenoy VK, Reddy JM, Shetty BT, Saldanha S. Flexible dentures: A flexible option to treat edentulous patients. J Nepal Dent Assoc. 2010;11(1):85-7.
33
ORIGINAL_ARTICLE
Novel Cases of Diamond Blackfan Anaemia in Two Nigerian Toddlers: Roadmap for Care in Resource-Limited Nations
Diamond Blackfan anaemia (DBA) is a rare cause of anaemia in children. To the best of our knowledge, these are the first cases reported in Nigeria. Two toddlers with a history of recurrent anaemia, which started within the first three months of life. Investigations conducted in both cases yielded macrocytic anaemia, reticulocytopenia, and bone marrow biopsy, indicating reduced erythroid precursors. Erythrocyte adenosine deaminase was elevated in a subject while the other had abnormal genitalia. Only one subject achieved remission following two months of therapy with steroids. A high index of suspicion for DBA should be drawn in children with a history of recurrent non-haemolytic anaemia from infancy refractory to available basic therapy.
http://www.ijsrdms.com/article_130775_275045c1bb6ba625c8b02d2fe3a894ea.pdf
2021-06-01
101
104
10.30485/ijsrdms.2021.282666.1148
Blood transfusion
Diamond Blackfan Anaemia
Erythroid precursors
Haematopoietic cell transplant
Prednisolone
pure red cell aplasia
Thomas
Ulasi
tomulasi67@gmail.com
1
Department of Paediatrics, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
AUTHOR
Chisom
Nri-Ezedi
chisomnriezedi@gmail.com
2
Department of Paediatrics, Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
LEAD_AUTHOR
Ogochukwu
Ofiaeli
ofiaeliogochukwuchioma@gmail.com
3
Department of Paediatrics, Faculty of Medicine, Nnamdi Azikiwe University, Anambra, Nigeria
AUTHOR
Egbunike
Chijioke
dregbusjeffo2015@gmail.com
4
Department of Haematology, Faculty of Medicine, Nnamdi Azikiwe University, Anambra, Nigeria
AUTHOR
[1] Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood, The Journal of the American Society of Hematology. 2011;117(9):2567-76. https://doi.org/10.1182/blood-2010-07-295238.
1
[2] Aspesi A, Pavesi E, Ferrante D. THE RIBOSOMAL BASIS OF DIAMOND-BLACKFAN ANEMIA: MUTATION AND DATABASE UPDATE.2010;31(12):1269-79. http://dx.doi.org/10.1002/humu.21383.
2
[3] Lahoti A, Harris YT, Speiser PW, Atsidaftos E, Lipton JM, Vlachos A. Endocrine dysfunction in Diamond–Blackfan anemia (DBA): A report from the DBA Registry (DBAR). Pediatric blood & cancer. 2016;63(2):306-12. https://doi.org/10.1002/pbc.25780.
3
[4] McFarren A, Jayabose S, Ozkaynak MF, Tugal O, Sandoval C. Cleft palate, bilateral external auditory canal atresia, and other midline defects associated with Diamond-Blackfan anemia: case report. Journal of pediatric hematology/oncology. 2007;29(5):338-40. doi: 10.1097/MPH.0b013e31805d8f45.
4
[5] Bessler M, Mason P, Link D, DB W. Inherited bone marrow failure syndromes. In: Orkin S, Fishe r DE, Ginsburg D, Look A, Lux S, Nathan D, editors. Nathan and Oski’s hematology and oncology of infancy and childhood. Philadelphia: Saunders Elseviers; 2015.
5
[6] Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the UK: analysis of 80 cases from a 20-year birth cohort. British journal of haematology. 1996;94(4):645-53. https://doi.org/10.1046/j.1365-2141.1996.d01-1839.x.
6
[7] Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-76. DOI: 10.1111/j.1365-2141.2008.07269.x.
7
[8] Halperin DS, Freedman MH. Diamond-blackfan anemia: etiology, pathophysiology, and treatment. The American journal of pediatric hematology/oncology. 1989;11(4):380-94.
8
[9] Willig TN, Niemeyer CM, Leblanc T, Tiemann C, Robert A, Budde J, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. Pediatric research. 1999;46(5):553. https://doi.org/10.1203/00006450-199911000-00011.
9
[10] Aneke JC, Okocha CE. Blood transfusion safety; current status and challenges in Nigeria. Asian journal of transfusion science. 2017;11(1):1-5. doi: 10.4103/0973-6247.200781.
10
[11] Gordon RR, Varadi S. Congenital hypoplastic anaemia (pure red-cell anaemia) with periodic erythroblastopenia. The Lancet. 1962;279(7224):296-9. https://doi.org/10.1016/S0140-6736(62)91245-X.
11
[12] Guillozet N, JF M. Congenital hypoplastic red cell anaemia of childhood:(the Blackfan-diamond syndrome). Case report, diagnosis and management.
12
[13] Wranne L. Transient erythroblastopenia in infancy and childhood. Scandinavian journal of haematology. 1970;7(2):76-81. https://doi.org/10.1111/j.1600-0609.1970.tb01872.x.
13
[14] Noel CB. Diamond–Blackfan anemia RPL35A: a case report. Journal of medical case reports. 2019;13(1):185-89. https://doi.org/10.1186/s13256-019-2127-3.
14